



ATMOFIZER TECHNOLOGIES INC. RECEIVES NOTICE OF ALLOWANCE FROM USPTO

Key Patent for Atmofizer's air purification technology

March 9, 2022, Vancouver, British Columbia – Atmofizer Technologies Inc. (the “**Company**” or “**Atmofizer**”) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) announces today that the United States Patent and Trademark Office (the “**USPTO**”) has issued a notice of allowance for claims related to the Company's air and water purification technology.

The allowed patent application, titled, “Ultra-Fine Particle Aggregation, Neutralization and Filtration” (US Patent Application No. 17/471,610) provides broad protection for the application of the Company's air and water purification technology.

“This notice of allowance provides further validation of our novel approach to air and water purification technology and enables Atmofizer to confidently pursue further development of its technology.” said Olivier Centner, Chief Executive Officer of Atmofizer Technologies Inc.

Joel Weiss, Managing Partner of Weiss & Arons, LLP, and Atmofizer's IP counsel, stated, “allowance of the Atmofizer Patent validates the Atmofizer technological solutions to real technological problems and signifies the relevance, on a go-forward basis, of Atmofizer in the air and water purification markets.”

Olivier further states, “This patent is a critical step in protecting our technology and establishing ourselves as the leaders in purifying air from even the smallest ultra fine particles, the ones that get past our bodies natural defenses, into our blood and even our brains. COVID has raised awareness of air quality, the market is growing exponentially and Joel and his team have done a fantastic job ensuring we protect our technology so we can focus on commercialization.”

A notice of allowance is issued after the USPTO makes the determination that a patent should be granted from an application. A patent from the recently allowed application is pending issuance and is expected to be issued in the near future.



For additional information on the Company, please contact:

Olivier Centner
Chief Executive Officer
Telephone: 305-902-1858
Email: info@atmofizer.com

For Media Inquiries and Investor Relations, please contact:

Email: info@atmofizer.com

About Atmofizer Technologies Inc.

Atmofizer's consumer and industrial solutions are based on its patent-protected and patent pending technology for ultrafine particle agglomeration and neutralization. This capability creates a revolutionary and more efficient method for addressing the wide range of dangerous nano-scale particles, viruses and bacteria that are too small to be effectively managed by conventional HEPA filters and ultraviolet lights. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while lowering customers' operational costs.

Atmofizing air refers to the process of using ultrasonic acoustic waves to agglomerate (cluster together) small particles into a larger target that is then radiated by ultraviolet light to neutralize their harmful properties, making the air you breath less hazardous to your health. Using units that atmofize air in tandem with HEPA filters can make the HEPA filters work more efficiently, enable the use of a less-powerful filter and result in a cleaner and longer-lasting filter that reduces operating costs and is less of a health hazard to clean or replace.

Atmofizer is patent-pending and patent-protected sole source of technology to atmofize air and is applying its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that integrate Atmofizer technology into their own products under license. Atmofizer's owned and licensed product lines include wearable, portable and mobile use for personal air treatment, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential applications.

Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain

events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, the granting of US Patent Application No. 17/471,610 and the business and strategic plans of the Company.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable laws and governmental regulations relating to its commercial products; the ability of the Company to protect its intellectual property; impacts to the business and operations of the Company due to the COVID-19 pandemic; the conflict in eastern Europe; having only a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.